KRAS Gene Mutation clinical trials at UC Cancer
1 research study open to eligible people
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
open to eligible people ages 18 years and up
Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.
Our lead scientists for KRAS Gene Mutation medical studies include Lee Rosen.